TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +34.31%. A quarter ago, it was expected that this company would post a loss of $0.35 per share when it actually produced a loss of $0.28, delivering a surprise of +20%.Over the last four quarters, the company ha ...